SK Biopharmaceuticals

Update in progress

326030.KS (KSE)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

SK Biopharmaceuticals Co., Ltd. is a South Korean pharmaceutical company focused on researching, developing and commercializing drugs for central nervous system disorders. It markets Cenobamate for epilepsy and Solriamfetol, and is developing a pipeline that includes Carisbamate (Phase 3 for Lennox-Gastaut syndrome), Relenopride (Phase 2 for a rare neurological disease), and several early-stage candidates such as SKL24741, SKL20540, SKL27969, SKL13865 and SKL-PSY for various CNS conditions. Founded 1993, based in Seongnam, and a subsidiary of SK Inc.

Company score

Sentiment: 0.55; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.32; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.11; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.12; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.33; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive